Ozagrel can selectively inhibit thromboxane synthase, thereby inhibiting the production of thromboxane A2 and promoting the production of prostacyclin (PGI2), improving the balance between the two, ultimately inhibiting platelet aggregation and reducing vasospasm, and improving local brain function. Microcirculation and energy metabolism disorders during ischemia
Let us work together to protect precious health